Comparing the current results to its competitors, Syros Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.34 %, recorded in the same quarter.
Syros Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 547.1 %
Syros Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates within the pharmaceutical and biotechnology industries, which are marked by rapid technological advancements and intense competition. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company focuses on developing cancer therapies and faces competition from divisions of large pharmaceutical companies and biotechnology firms of various sizes. Current cancer treatments include surgery, radiation, chemotherapy, hormone therapy, and targeted drug therapy, often used in combination. Competitors may possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions have led to resource concentration among fewer competitors.
Publicly Traded Peers of Syros Pharmaceuticals Inc
Lantern Pharma Inc Share Performance
-34.12%
30 Days
Lantern Pharma Inc
Profile
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.
Sources:
Syros Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Syros Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
